Curated News
By: NewsRamp Editorial Staff
November 13, 2026
Vycor Medical Q3 Revenue Falls 19% but Nine-Month Operating Profit Rises
TLDR
- Vycor Medical's NovaVision revenue grew 41% in Q3 2026, signaling upside in its stroke vision-recovery therapy despite an overall revenue dip.
- Vycor Medical's ViewSite Brain Access System revenue fell 18% in Q3 2026, offset by 41% NovaVision growth and higher nine-month operating profit.
- Vycor Medical's ViewSite system and NovaVision therapies help patients recover from brain injury and vision loss, improving lives through less invasive care.
- Vycor Medical now has 54 peer-reviewed papers on its ViewSite Brain Access System, including a Japanese study using an exoscope for hemorrhage evacuation.
Impact - Why it Matters
Vycor’s latest earnings underscore the volatility inherent in small-cap medical device sales, where bulk orders and hospital adoption cycles can swing quarterly comparisons. Yet the company’s ability to expand its operating profit over nine months despite lower revenue signals disciplined cost management and a resilient gross margin above 80%. The growing body of peer-reviewed evidence—now 54 studies—strengthens the clinical case for VBAS, which could drive broader adoption among neurosurgeons seeking minimally invasive tools that reduce tissue damage and improve patient outcomes. For investors, the continued double-digit growth at NovaVision, though still small, offers a glimpse of long-term optionality in the vision rehabilitation market. As Vycor navigates lumpy international sales and invests in clinical validation, its financial health and innovative pipeline remain key to its trajectory in the competitive neurosurgical space.
Summary
Vycor Medical, Inc. (OTCQB: VYCO), a Boca Raton-based medical device company, reported financial results for the three and nine months ended September 30, 2026. The company operates two divisions: Vycor Medical, which produces the ViewSite Brain Access System (VBAS) for neurosurgeons, and NovaVision, a development-stage business offering vision rehabilitation therapies for patients recovering from stroke or brain injury. Revenue for the third quarter fell 19% to $414,895, while nine-month revenue declined 11% to $1,291,699. The Vycor Medical division saw a Q3 revenue decrease of 18% to $402,048 and a nine-month decrease of 11% to $1,243,713. Management attributed the decline primarily to unusually high U.S. sales in the 2025 period from new hospitals and bulk orders, partially offset by increased international sales in Q3. Despite lower revenue, operating profit for the nine months rose to $80,083 from $70,425, and non-GAAP operating profit was $125,751 versus $166,262 in the prior year. Gross margins remained strong at 85% for Q3 and 83% for the nine-month period.
During 2026, four new peer-reviewed studies on VBAS were published, bringing the total to 54 peer-reviewed papers plus 14 other clinical papers. These studies highlighted the device’s effectiveness in pediatric tumor resection, safer tumor removal with fewer neurological deficits compared to traditional blade retractors, minimally invasive resection of posterior fossa metastases, and intracerebral hemorrhage evacuation. The NovaVision division, still in development, posted Q3 revenue of $12,847, a 41% increase, and nine-month revenue of $47,986, up 11%. The company also provided non-GAAP reconciliations, excluding non-cash depreciation and stock-based compensation. For more information, viewers can watch the VBAS Video and the NovaVision Video, or visit www.vycormedical.com. The original release is available on www.newmediawire.com.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, Vycor Medical Q3 Revenue Falls 19% but Nine-Month Operating Profit Rises
